Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 33.25
(-1.77%)
TWD 33.25
(-1.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 437.58 Million TWD | -15.29% |
| 2022 | 516.57 Million TWD | 4.87% |
| 2021 | 492.56 Million TWD | 17.89% |
| 2020 | 417.83 Million TWD | 20.23% |
| 2019 | 347.52 Million TWD | 8.39% |
| 2018 | 320.61 Million TWD | -2.76% |
| 2017 | 329.73 Million TWD | 4.24% |
| 2016 | 316.33 Million TWD | 3.05% |
| 2015 | 306.95 Million TWD | 12.27% |
| 2014 | 273.4 Million TWD | -1.03% |
| 2013 | 276.26 Million TWD | -6.16% |
| 2012 | 294.38 Million TWD | 3.31% |
| 2011 | 284.94 Million TWD | 15.72% |
| 2010 | 246.23 Million TWD | 6.83% |
| 2009 | 230.49 Million TWD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 92.07 Million TWD | 5.72% |
| 2024 Q2 | 83.82 Million TWD | 2.37% |
| 2023 Q1 | 142.94 Million TWD | -2.18% |
| 2023 Q4 | 87.09 Million TWD | -20.95% |
| 2023 Q2 | 126.04 Million TWD | -11.83% |
| 2023 FY | 437.58 Million TWD | -15.29% |
| 2023 Q3 | 110.17 Million TWD | -12.59% |
| 2022 Q1 | 134.15 Million TWD | -14.21% |
| 2022 Q4 | 146.13 Million TWD | 27.92% |
| 2022 Q3 | 114.24 Million TWD | -6.39% |
| 2022 FY | 516.57 Million TWD | 4.87% |
| 2022 Q2 | 122.04 Million TWD | -9.03% |
| 2021 Q2 | 101.82 Million TWD | -2.05% |
| 2021 Q3 | 130.41 Million TWD | 28.08% |
| 2021 FY | 492.56 Million TWD | 17.89% |
| 2021 Q1 | 103.95 Million TWD | -26.34% |
| 2021 Q4 | 156.37 Million TWD | 19.91% |
| 2020 Q4 | 141.12 Million TWD | 51.69% |
| 2020 Q3 | 93.03 Million TWD | -3.78% |
| 2020 Q1 | 86.97 Million TWD | -3.43% |
| 2020 FY | 417.83 Million TWD | 20.23% |
| 2020 Q2 | 96.69 Million TWD | 11.17% |
| 2019 Q4 | 90.06 Million TWD | 13.23% |
| 2019 FY | 347.52 Million TWD | 8.39% |
| 2019 Q3 | 79.54 Million TWD | -11.17% |
| 2019 Q2 | 89.54 Million TWD | 1.33% |
| 2019 Q1 | 88.36 Million TWD | 1.99% |
| 2018 FY | 320.61 Million TWD | -2.76% |
| 2018 Q3 | 65.81 Million TWD | -24.63% |
| 2018 Q2 | 87.31 Million TWD | 8.0% |
| 2018 Q1 | 80.84 Million TWD | -9.48% |
| 2018 Q4 | 86.64 Million TWD | 31.65% |
| 2017 Q1 | 81.97 Million TWD | 0.97% |
| 2017 Q3 | 82 Million TWD | 7.3% |
| 2017 Q2 | 76.43 Million TWD | -6.77% |
| 2017 Q4 | 89.31 Million TWD | 8.91% |
| 2017 FY | 329.73 Million TWD | 4.24% |
| 2016 Q4 | 81.19 Million TWD | 5.1% |
| 2016 Q1 | 81.97 Million TWD | -0.92% |
| 2016 Q3 | 77.25 Million TWD | 1.75% |
| 2016 FY | 316.33 Million TWD | 3.05% |
| 2016 Q2 | 75.92 Million TWD | -7.38% |
| 2015 Q3 | 75.99 Million TWD | 2.07% |
| 2015 FY | 306.95 Million TWD | 12.27% |
| 2015 Q1 | 73.78 Million TWD | 7.98% |
| 2015 Q2 | 74.45 Million TWD | 0.91% |
| 2015 Q4 | 82.73 Million TWD | 8.87% |
| 2014 Q2 | 66.03 Million TWD | -5.53% |
| 2014 Q3 | 69.15 Million TWD | 4.73% |
| 2014 Q1 | 69.89 Million TWD | 1.74% |
| 2014 FY | 273.4 Million TWD | -1.03% |
| 2014 Q4 | 68.32 Million TWD | -1.19% |
| 2013 Q1 | 70.05 Million TWD | 45.18% |
| 2013 FY | 276.26 Million TWD | -6.16% |
| 2013 Q3 | 68.7 Million TWD | -0.14% |
| 2013 Q4 | 68.69 Million TWD | -0.01% |
| 2013 Q2 | 68.8 Million TWD | -1.78% |
| 2012 Q2 | 87.79 Million TWD | 9.03% |
| 2012 FY | 294.38 Million TWD | 3.31% |
| 2012 Q4 | 48.25 Million TWD | -38.51% |
| 2012 Q3 | 78.46 Million TWD | -10.62% |
| 2012 Q1 | 80.52 Million TWD | -3.94% |
| 2011 Q2 | 67.97 Million TWD | 18.06% |
| 2011 Q1 | 57.57 Million TWD | -18.27% |
| 2011 Q3 | 75.56 Million TWD | 11.16% |
| 2011 FY | 284.94 Million TWD | 15.72% |
| 2011 Q4 | 83.82 Million TWD | 10.94% |
| 2010 Q1 | 57.27 Million TWD | 0.0% |
| 2010 FY | 246.23 Million TWD | 6.83% |
| 2010 Q2 | 61.23 Million TWD | 6.9% |
| 2010 Q4 | 70.44 Million TWD | 22.99% |
| 2010 Q3 | 57.28 Million TWD | -6.45% |
| 2009 FY | 230.49 Million TWD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Apex Biotechnology Corp. | 389.4 Million TWD | -12.374% |
| Sinphar Pharmaceutical Co.,Ltd. | 807.86 Million TWD | 45.835% |
| Panion & Bf Biotech Inc. | 817.56 Million TWD | 46.477% |
| GenMont Biotech Incorporation | 204.2 Million TWD | -114.287% |
| Abnova (Taiwan) Corporation | 126.72 Million TWD | -245.312% |
| Adimmune Corporation | 1.13 Billion TWD | 61.402% |
| Tanvex BioPharma, Inc. | 2.16 Billion TWD | 79.746% |
| Polaris Group | -3.06 Million TWD | 14376.77% |
| Energenesis Biomedical CO.,LTD. | 267.06 Million TWD | -63.849% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -2345.008% |
| PELL Bio-Med Technology Co. Ltd. | 385.1 Million TWD | -13.627% |